Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024. Novartis ...

American Express is a top financial stock to round out your portfolio. The company has been generating record numbers even ...

Novartis reported a strong Q3 2024 with 9% YoY sales growth, largely driven by its top four drugs. Pluvicto and Leqvio saw significant growth, but investor disappointment stemmed from a revenue ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00. Etzer Darout’s rating is based on a thorough analysis of ...

On Thursday, Novartis AG (NYSE:NVS) raised its mid-term sales guidance, increasing its compound annual growth rate (CAGR) target to 6% from 5% for 2023-2028. The upgrade reflects performance from ...

Novartis (NVS) has announced that it will acquire Tourmaline Bio, Inc. (TRML), a New York-based, publicly traded clinical-stage biopharmaceutical company, for $1.4 billion. The acquisition will add ...

IgA nephropathy, also known as Berger's disease, is an autoimmune kidney disease in which clumps of antibodies, specifically immunoglobulin A (IgA), accumulate in the kidney's filters, leading to ...